Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Bipolar Depression

NCT03965871 is registered in ClinicalTrials.gov with Celon Pharma SA as lead sponsor.

NCT NCT03965871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03965871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-blind, Randomised, Placebo - Controlled Phase II Study to Assess Efficacy, Safety and Pharmacokinetics of Inhaled Esketamine in Subject With Treatment-resistant Bipolar Depression
Lead sponsor
Celon Pharma SA
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2019
Completion date
February 19, 2021
Enrollment
88 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression